Head and Neck Neoplasms Clinical Trial
Official title:
Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole
The purpose of this clinical research study is to answer the following questions using
18F-fluoromisonidazole as an imaging agent:
1. Do cells exist in human tumors that are at very low oxygen levels (hypoxic cells)?
2. If hypoxic cells exist in human tumors, do they effect the ability of radiotherapy to
control human tumors?
3. Can Positron Emission Tomography (PET scanning) detect hypoxic cells in human tumors?
Hypoxic (low oxygen) cells have long been known to exist in animal tumors. It is also known
that hypoxic cells are more difficult to eliminate with radiotherapy than tumor cells at
normal levels of oxygen (normoxic cells). However, the extent to which hypoxic cells limit
the curability of human tumors is uncertain. To determine if hypoxic cells exist in human
tumors and how hypoxic cells might influence the efficacy of radiotherapy, this study
involves direct measurements of oxygen levels in human tumors compared to the tumor uptake
of the experimental drug, 18F-fluoromisonidazole (18F-FMISO), visualized with PET scanning.
18F-fluoromisonidazole has been used with PET imaging to tell the difference between growing
tumors which have high and low oxygen content.
Before beginning radiotherapy, a PET scan (series of pictures, 20 min. scan) will be
performed at 2 hours after an intravenous injection of a small amount of radioactive traces
drug, 18F-fluoromisonidazole (18F-FMISO) to observe the active hypoxia tumors areas. Upon
completion of the 18F-FMISO PET scan, direct oxygen measurements will be obtained by placing
a small needle into the tumor under computer tomographic (CT) guidance. The PET scan and
needle measurements will be repeated every 4 weeks into the course of radiotherapy and again
after the completion of radiotherapy. The measurement obtained by 18F-FMISO PET scanning
(non-invasive technique) and by direct needle measurements (invasive technique) will be
correlated with the eventual treatment outcome for future use.
;
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05980598 -
TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma
|
Phase 2 | |
Completed |
NCT02548377 -
Remote Ischemic Preconditioning in Head and Neck Cancer Reconstruction - A Randomized Controlled Trial
|
N/A | |
Active, not recruiting |
NCT02229656 -
Olaparib and Radiotherapy in Head and Neck Cancer
|
Phase 1 | |
Not yet recruiting |
NCT06289049 -
Heavy Strength Training in Head and Neck Cancer Survivors
|
Phase 2 | |
Not yet recruiting |
NCT06347185 -
Simultaneous Care in Recurrent and/or Metastatic Head and Neck Cancer: the SupCare Study
|
N/A | |
Terminated |
NCT02975739 -
Feasibility of Holmium-166 Micro Brachytherapy in Head and Neck Tumors
|
N/A | |
Recruiting |
NCT00982436 -
Neoadjuvant Cisplatin/Docetaxel (CDDP/TXT) and Chemoradiation for Head and Neck Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01025518 -
DAHANCA 25A: Resistance Training and Dietary Supplements as Intervention for Regaining Muscle Mass Following Radiotherapy in Head and Neck Cancer Patients
|
N/A | |
Active, not recruiting |
NCT00248235 -
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT00135161 -
Feasibility Study of Incorporating 18F-FDG-PET Imaging in Radiotherapy for Head and Neck Cancer
|
Phase 1 | |
Terminated |
NCT00073450 -
Study of Lonafarnib in Patients With Recurrent Squamous Cell Carcinoma of the Head and Neck (Study P02530)
|
Phase 2 | |
Not yet recruiting |
NCT06458517 -
Evaluation of Two Methods of Administration of Photobiomodulation in the Context of the Prevention and Treatment of Mucositis Induced by Radiotherapy, During the Treatment of Head and Neck Cancers
|
N/A | |
Completed |
NCT05269342 -
Nurse-led Exercise Improves Shoulder Pain, Shoulder Disability, and Quality of Life in Head and Neck Cancer
|
N/A | |
Recruiting |
NCT05544136 -
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer
|
Phase 2 | |
Terminated |
NCT03286972 -
PET/MRI to Enhance Precision Guidance in Head and Neck Radiation Treatment Planning
|
||
Recruiting |
NCT04435938 -
A Study of SBRT for Squamous Cell Carcinoma of the Head and Neck
|
Phase 2 | |
Recruiting |
NCT03975465 -
EMST and Swallowing in Long-Term Survivors of HNCA
|
N/A | |
Recruiting |
NCT03678649 -
A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC
|
Phase 2 | |
Completed |
NCT06446570 -
Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
|
Phase 2 | |
Completed |
NCT03292250 -
Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)]
|
Phase 2 |